Pharma prepares for CDMO growth in 2025 as CPHI Milan reports record attendance
December 13, 2024CPHI Milan, CPhI, networking
13 December 2024 – Amsterdam, the Netherlands – CPHI Milan – the world’s largest pharma event – hosted last month …
Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company
December 12, 2024Corporate, Deep Science Ventures, General Inception, fibrosis, venture
12 December 2024 – London, UK, and Palo Alto, CA, US – Deep Science Ventures, a UK-based venture studio, and …
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
December 10, 2024Mounjaro, NICE, lilly, weight-loss
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute for Health and Care Excellence …
UCB presents epilepsy research at American Epilepsy Society Annual Meeting
December 9, 2024Research and Development American Epilepsy Society, Dravet Syndrome, Neurology, UCB, sleep
Belgian-based biopharmaceutical company UCB has announced it will present 32 abstracts at the American Epilepsy Society (AES) Annual Meeting – …
Gemma Cathcart appointed managing partner at Langland
November 25, 2024Corporate, Langland
Langland, a medical life sciences company with focuses on areas surrounding Clinical Trial experience, Medical Strategy and Education, Public Relations …
Ceryx Medical Initiates First-In-Human Study of the Cysoni™ RSA Pacemaker
November 21, 2024Ceryx Medical, Devices, biotech
Ceryx’s Cysoni pacing technology is designed to provide superior therapeutic outcomes for Heart Failure patients by improving cardiac output using …
Glox Therapeutics Awarded £1M PACE Grant to Accelerate Development of Precision Antibiotics Against Antimicrobial-resistant Pathogens
November 20, 2024AMR Week, Glox Therapeutics, antimicrobial resistance
Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae PACE provides funding …
Great Place To Work® and Fortune Name Chiesi Group No. 23in 2024 World’s Best Workplaces™ List
November 19, 2024Chiesi, Corporate, best workplace
Chiesi is the only European pharmaceutical company and the first Italian company ever to be included in the World’s Best …
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
November 18, 2024barinthius Bio
Eight participants achieved HBsAg loss at any time. Two participants met criteria for functional cure. Two participants who discontinued NUC …
Antibacterial peptides instrumental in efficiency against resistant bacteria
November 18, 2024Research and Development AMR, Chalmers Institute of Technology, Infections and infestations, MRSA, antibacterial peptides
This month, the Chalmers University of Technology in Sweden have published the results of a study demonstrating that resistant bacteria, …
Spinal cord stimulator with AI technology receives CE Mark certification
November 13, 2024Research and Development AI, EU, Nevro, Pain, spinal cord stimulation
The HFC iQ, a personalised spinal cord stimulation (SCS) system developed by Nevro that leverages AI technology to manage chronic …
J&J seek approval for first drug to treat high-risk smoldering myeloma
November 13, 2024Research and Development FDA, J&J, Rare Diseases, bone marrow
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and Drug Agency (FDA) and the …
Theramex receives recommendation for YSELTY in Scotland
November 11, 2024Research and Development Pain, Reproductive health, appproval, tumours, women's health
Theramex, a dedicated women’s health company, have announced that the Scottish Medicines Consortium (SMC) have recommended YSELTY (linzagolix) for the …
CMS commences formal review for Topical Oxygen Therapy coverage
November 11, 2024Wound Healing, topical oxygen therapy, wound care
11 November 2024 AOTI, INC. (AIM: AOTI), a medical technology group focussed on the durable healing of wounds and prevention …
Johnson & Johnson receive MHRA approval for BALVERSA
November 8, 2024Research and Development J&J Innovative Medicine, Oncology, Urology, bladder cancer
BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment …
SolasCure partners with US Army for better wound care technology
November 6, 2024Research and Development Dressings, hosiery & appliances, Solascare, US army, wound care, wound gel
SolasCure, a biotechnology company which is dedicated to working towards filling the current market gap in debridement – the removal …
NorthWest EHealth (NWEH) announces a pilot to test a new model for finding and recruiting participants for clinical trials using the Clinical Practice Research Datalink
November 5, 2024Research and Development NorthWest Ehealth, clinical trials
The pilot aims to speed up the process for safely and securely finding participants for UK clinical trials, improving efficiencies …
FlyPharma Vienna 2024: An Event to Remember!
November 4, 2024Corporate, FlyPharma 2024, Samedan, event
Samedan announces that their 2024 FlyPharma Conference, held in Office Park 4, Vienna AirportCity, Austria, has officially concluded! As a …
Valneva Scotland supports local cancer charity Team Jak Foundation
October 31, 2024Support Services Oncology, Scotland, Valneva Scotland, cancer charity, paediarics, vaccines
Valneva Scotland, the country’s largest vaccine producer, has partnered with local West Lothian-headquartered charity, Team Jak, helping towards the organisation’s …
University of Edinburgh spinout Kynos Therapeutics acquired by Dr. Falk Pharma
October 30, 2024Research and Development Edinburgh, Internal Medicine, Microbiology, acquisitions, biopharma, inhibitors
Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase (KMO) inhibitors – has been …
Latest content
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner
